 | Stephen I WassermanDepartment of Medicine, University of California San Diego, USA | Medicine/Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, California, USA ... |
KOL Resume for Stephen I Wasserman (disease, otitis, nonsuppurative otitis media, nonsuppurative, media)
| Year | |
|---|---|
| 2019 | Department of Medicine, University of California San Diego, USA |
| 2017 | Medicine/Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, California, USA Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, Calif |
| 2016 | School of Medicine—Department of Medicine, Rheumatology, Allergy and Immunology Division, University of California San Diego, 9500 Gilman Drive—MC#0628, 92093-0628, La Jolla, CA, USA |
| 2015 | Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA USA |
| 2014 | Departments of Medicine/Allergy & Immunology, University of California, San Diego, La Jolla, CA 92093 USA Division of Allergy-Immunology, Department of Medicine, University of California, San Diego School of Medicine and VA Medical Center, La Jolla, California, United States of America |
| 2013 | University of California, San Diego, Calif |
| 2012 | Department of Medicine, University of California, San Diego (Drs Ramsdell and Wasserman) |
| 2011 | Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, San Diego, California, USA University of California–San Diego, San Diego, Calif Departments of Medicine/Rheumatology, Allergy and Immunology |
| 2010 | University of California, San Diego, La Jolla, CA 92037; Division of Rheumatology, Allergy and Immunology, Department of Medicine, and |
| 2009 | Department of Medicine/Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA |
| 2008 | Division of Allergy, Immunology, Department of Medicine, University of California, San Diego, Calif For a full list of affiliation details please refer to the Acknowledgements section. UCSD, La Jolla, CA |
| 2006 | Department of Medicine, Division of Otolaryngology, UCSD School of Medicine and VA Medical Center, La Jolla, CA 92093-0666, USA |
| 2005 | Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of California, San Diego School of Medicine, La Jolla |
| 2003 | Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California-San Diego, Stein Clinical Research Building, Room 244, 9500 Gilman Drive, La Jolla, CA 92093-0637, USA. |
| 2002 | the Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California at San Diego, La Jolla. La Jolla, Calif |
| 2000 | Department of Medicine, University of California, San Diego, San Diego, Calif |
| 1996 | Department of Medicine Division of Allergy, University of California, San Diego, California Charlottesville, Va., Dayton and Cincinnati, Ohio, Galveston, Texas, New Orleans, La., Greenville, N.C., and San Diego, Calif |
| 1995 | San Diego, Calif., Rochester and Minneapolis, Minn., and Seattle, Wash. |
| 1994 | University of California, San Diego Medical Center, CA 92103-199. |
| 1993 | From the Department of Medicine, Division of Allergy, University of California, San Diego School of Medicine, San Diego, Calif., USA |
| 1992 | Department of Medicine, Division of Allergy, Immunology, San Diego, Calif., USA |
| 1991 | University of California at San Diego Medical Center. Richmond, Va., USA |
| 1990 | Department of Medicine, University of California, San Diego92103. Jackson Memorial Hospital Pulmonary Function Laboratory, Miami Division of Pulmonary and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh National Jewish Center for Immunology and Respiratory Medicine, Denver |
| 1989 | Division of Allergy/Immunology, University of California, San Diego. |
| 1987 | From the Division of Allergy and Immunology, University of California at San Diego School of Medicine, San Diego, California USA Divisions of Dermatology and Rheumatology, University of California, San Diego, California, U.S.A. |
| 1986 | From the Department of Pediatrics and Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colo., USA |
| 1985 | From the Division of Otolaryngology, Department of Surgery, and the Division of Allergy, Department of Medicine, University of California San Diego Medical School, La Jolla. Dr Ryan is the recipient of Research Career Development Award NS 00176 from the NIH/NINCDS, and Dr Wasserman the recipient of Allergic Diseases Academic Award AI 00451 from the NIH/NIAID. University of California at San Diego Medical Center, San Diego California, USA |
| 1984 | Associate Professor of Medicine, Division of Rheumatology, University of California Medical Center, San Diego From the Scripps Clinic and Research Foundation, La Jolla, California, USA |
| 1983 | From the Allergy Section, Division of Rheumatology/Allergy, Department of Medicine, School of Medicine, University of California, San Diego, Calif., USA Division of Rheumatic DIseases, University of California, 92103, San Diego, CA University of California, San Diego, University Hospital |
| 1982 | Division of Rheumatology and Allergy, Department of Medicine, University of California, San Diego, California 92103 USA |
| 1981 | Associate Professor of Medicine, University of California, San Diego, School of Medicine; Chief, Adult Allergy, University of California, San Diego, California |
| 1980 | From the Department of Dermatology, Harvard Medical School, and Robert B. Brigham and Peter Bent Brigham Divisions of the Affiliated Hospitals Center, Boston, Mass. USA Divisions of Dermatology, Departments of Medicine, Robert B. Brigham and Peter Bent Brigham Divisions of the Affiliated Hospitals Center Inc., Boston, Massachusetts, U.S.A. |
| 1979 | From the Departments of Dermatology and Medicine, Harvard Medical School; Divisions of Dermatology, Departments of Medicine, Robert B. and Peter Bent Brigham Divisions of the Affiliated Hospitals Center, Boston, Massachusetts Boston, Mass., USA |
| 1978 | Departments of Medicine, Harvard Medical School and the Robert B. Brigham Division of the Affiliated Hospitals Center, Inc., Boston, Massachusetts 02120 USA |
| 1976 | Departments of Medicine, Harvard Medical School, The Robert B. Brigham Hospital, 02120, Boston, Mass., USA Department of Medicine, Robert B. Brigham Hospital and Harvard Medical School, Boston, Massachusetts, U.S.A. |
| 1974 | From the Departments of Medicine, Harvard Medical School and Robert B. Brigham Hospital, Boston, Massachusetts 02120 |
Prominent publications by Stephen I Wasserman
BACKGROUND: Some studies suggest that patients with asthma who are homozygous for arginine at the 16th amino acid position of the beta2-adrenergic receptor (B16 Arg/Arg) benefit less from treatment with longacting beta2 agonists and inhaled corticosteroids than do those homozygous for glycine (B16 Gly/Gly). We investigated whether there is a genotype-specific response to treatment with a longacting beta2 agonist in combination with inhaled corticosteroid.
METHODS: In this multicentre, ...
| Known for Inhaled Corticosteroid | Arg Gly | Adrenergic Receptor | Treatment Salmeterol | Longacting Β2 |
Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway
[ PUBLICATION ]
To assess whether mast cell and eosinophil (EOS) degranulation occurs in the airway of subjects with moderately symptomatic asthma, we have measured levels of preformed mast cell-derived mediators (histamine and tryptase) and EOS-derived mediators (major basic protein and EOS-derived neurotoxin) in bronchoalveolar lavage fluid (BALF) obtained from patients with symptomatic (N = 14) and asymptomatic asthma (N = 9) and patients without asthma (N = 6). Both the FEV1 (1.52 +/- 0.33 L:55% +/- ...
| Known for Mast Cell | Patients Asthma | Eosinophil Degranulation | Histamine Release | Major Basic Protein |
BACKGROUND: Long-acting beta-agonist (LABA) therapy improves symptoms in patients whose asthma is poorly controlled by an inhaled glucocorticoid alone. Alternative treatments for adults with uncontrolled asthma are needed.
METHODS: In a three-way, double-blind, triple-dummy crossover trial involving 210 patients with asthma, we evaluated the addition of tiotropium bromide (a long-acting anticholinergic agent approved for the treatment of chronic obstructive pulmonary disease but not ...
| Known for Uncontrolled Asthma | Tiotropium Bromide | Inhaled Glucocorticoid | P0001 Addition | Doubling Dose |
To determine whether cytokines are generated in vivo in subjects with asthma, we have measured cytokine levels (tumor necrosis factor [TNF], granulocyte-macrophage-colony-stimulating factor [GM-CSF], interleukin [IL]-1 alpha, IL-1 beta, IL-2, IL-4, and IL-6) in the airways of subjects with symptomatic (N = 24) and asymptomatic (N = 9) asthma with immunoassays (GM-CSF, IL-1 alpha, IL-1 beta, IL-2, and IL-4) or bioassays (TNF and IL-6) and the polymerase chain reaction (IL-1 beta and TNF). ...
| Known for Symptomatic Asthma | Il1 Beta | Levels Tnf | Polymerase Chain Reaction | Balf Patients |
Prevalence of dust mites in the homes of people with asthma living in eight different geographic areas of the United States
[ PUBLICATION ]
The density and species prevalence of dust mites were determined at various times over a 5-year-period in 252 homes of dust mite sensitive people with asthma who lived in eight geographic areas of the United States (Cincinnati, Ohio; New Orleans, La.; Memphis, Tenn.; Galveston, Texas; Greenville, N.C.; Delray Beach, Fla.; San Diego and Los Angeles, Calif.). The most common dust mites found in the homes were Dermatophagoides farinae (DF), D. pteronyssinus (DP), Euroglyphus maynei (EM), ...
| Known for United States | Dust Mites | New Orleans | Geographic Areas | San Diego |
CONTEXT: No consensus exists for adjusting inhaled corticosteroid therapy in patients with asthma. Approaches include adjustment at outpatient visits guided by physician assessment of asthma control (symptoms, rescue therapy, pulmonary function), based on exhaled nitric oxide, or on a day-to-day basis guided by symptoms.
OBJECTIVE: To determine if adjustment of inhaled corticosteroid therapy based on exhaled nitric oxide or day-to-day symptoms is superior to guideline-informed, physician ...
| Known for Inhaled Corticosteroid | Controlled Trial | Adults Asthma | Nitric Oxide | Based Adjustment |
Asthma has been recognized to consist of hyperresponsive airways and cellular inflammation. Allergen bronchoprovocation (BPC) may define the early (EAR) and late-phase asthmatic response (LAR). The LAR has now been associated with increased nonspecific airway hyperresponsiveness and cellular inflammation consisting of neutrophils and eosinophils. We used BPC to demonstrate EAR and LAR in 12 subjects with seasonal allergic asthma. One normal subject and one subject with asthma who had ...
| Known for Chemotactic Activity | Eca Nca | Eosinophils Neutrophils | Ear Lar | Asthmatic Response |
A 12-Week Dose-Ranging Study of Fluticasone Propionate Powder in the Treatment of Asthma
[ PUBLICATION ]
Fluticasone propionate (FP) administered via metered-dose inhaler is a potent corticosteroid effective in the treatment of asthma. To evaluate the efficacy and safety of FP powder administered via a breath-activated inhaler (Diskhaler), a multicenter, double-blind, randomized, placebo-controlled, parallel-group study was conducted in adolescent and adult patients (n = 331) with mild-to-moderate asthma previously treated with beta 2-agonist therapy alone. Patients received FP powder 50, ...
| Known for Treatment Asthma | Fluticasone Propionate Powder | Fp Placebo | Inhalation Adolescent Adrenergic | Greater Improvements |
Genome-wide association study identifies TH1 pathway genes associated with lung function in asthmatic patients
[ PUBLICATION ]
BACKGROUND: Recent meta-analyses of genome-wide association studies in general populations of European descent have identified 28 loci for lung function.
OBJECTIVE: We sought to identify novel lung function loci specifically for asthma and to confirm lung function loci identified in general populations.
METHODS: Genome-wide association studies of lung function (percent predicted FEV1 [ppFEV1], percent predicted forced vital capacity, and FEV1/forced vital capacity ratio) were performed ...
| Known for Lung Function | Pathway Genes | Asthmatic Patients | Asthma Susceptibility | Genomewide Association Studies |
Human nasal polyps from three ragweed-sensitive atopic patients released three chemical mediators: histamine, slow reacting substance of anaphylaxis, and eosinophil chemotactic factor of anaphylaxis on challenge with ragweed antigen. Polyps from four non-ragweed-sensitive subjects passively sensitized in vitro released the same chemical mediators. In a patient with chronic sinusitis and one with cystic fibrosis, dibutyryl cyclic adenosine 3′,5′-monophosphate and the beta adrenergic agent ...
| Known for Chemical Mediators | Human Nasal Polyps | Immunologic Release | Chronic Sinusitis | Cystic Fibrosis |
Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma
[ PUBLICATION ]
BACKGROUND: Improvement in lung function after macrolide antibiotic therapy has been attributed to reduction in bronchial infection by specific bacteria. However, the airway might be populated by a more diverse microbiota, and clinical features of asthma might be associated with characteristics of the airway microbiota present.
OBJECTIVE: We sought to determine whether relationships exist between the composition of the airway bacterial microbiota and clinical features of asthma using ...
| Known for Airway Microbiota | Bronchial Hyperresponsiveness | Controlled Asthma | Relative Abundance | Bacterial Diversity |
1-Alkyl-2-lyso-sn-glycero-3-phosphocholine:acetyl-CoA acetyltransferase catalyzes the conversion of biologically inactive lysophospholipid to bioactive platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, PAF) by an acetylation reaction. The activity of this enzyme in eosinophils isolated from patients with eosinophilia is stimulated (up to 4-fold) in a dose-, time-, and Ca2+/Mg2+-dependent manner after exposure to the eosinophil chemotactic factor of anaphylaxis ...
| Known for Paf Eosinophils | Eosinophil Chemotaxis | Activating Factor | Activity Enzyme | Ionophore A23187 |
BACKGROUND: Tiotropium has activity as an asthma controller. However, predictors of a positive response to tiotropium have not been described.
OBJECTIVE: We sought to describe individual and differential responses of asthmatic patients to salmeterol and tiotropium when added to an inhaled corticosteroid, as well as predictors of a positive clinical response.
METHODS: Data from the double-blind, 3-way, crossover National Heart, Lung, and Blood Institute's Asthma Clinical Research ...
| Known for Tiotropium Salmeterol | Positive Response | Inhaled Corticosteroid | Agents Asthma | Bromide Treatment |
Stephen I Wasserman: Influence Statistics
| Concept | World rank |
|---|---|
| nedocromil sodium drug | #1 |
| meningitis publication chemotaxis | #1 |
| skin respiratory eosinophil | #1 |
| acu syndromes | #1 |
| 12 subjects asthma | #1 |
| skin mucus membranes | #1 |
| chapter pathologic events | #1 |
| eca early | #1 |
| 1 10 20 | #1 |
| respiratory eosinophil | #1 |
| nod1 nod2mediated recognition | #1 |
| mastcell derived mediators | #1 |
| xanthine drugs ability | #1 |
| adenosine t84 cell | #1 |
| urticaria syndromes | #1 |
| histamine uva | #1 |
| lpiadpia | #1 |
| nonallergic signals | #1 |
| nonsteroidal nedocromil quinolones | #1 |
| plasma eca | #1 |
| mediators normal controls | #1 |
| cell membrane particulates | #1 |
| pathocenesis | #1 |
| mediator generation release | #1 |
| hormones nonsteroidal | #1 |
| release receptor recognition | #1 |
| 4 urticaria | #1 |
| vitro leukocyte migration | #1 |
| inhibition pafll release | #1 |
| effective antiasthmatic agent | #1 |
| analogs neca | #1 |
| urticaria release | #1 |
| receptor recognition mediators | #1 |
| bal mast cells | #1 |
| cellular inflammation neutrophils | #1 |
| ecfa a23187 | #1 |
| publication chemotaxis csf | #1 |
| pf4 detected | #1 |
| process physician assessments | #1 |
| 3hadenosine binding sites | #1 |
Open the FULL List in Excel | |
Key People For Otitis Media
Stephen I Wasserman:Expert Impact
Concepts for whichStephen I Wassermanhas direct influence:Otitis media, Mast cells, Mast cell, Cold urticaria, Middle ear, Nedocromil sodium, Animal ear, Asthma control.
Stephen I Wasserman:KOL impact
Concepts related to the work of other authors for whichfor which Stephen I Wasserman has influence:Mast cells, Otitis media, Severe asthma, Histamine release, Middle ear, Airway inflammation, Nedocromil sodium.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |